|
|
 |
| |
|
Home > Drug News > Colorado BioScience Association Endorses Referendums C & D
Colorado BioScience Association Endorses Referendums C & D
Colorado BioScience Association (CBSA) has published the second issue of its quarterly newsletter, "The CBSA FOCUS." Featured articles in the Summer 2005 publication cover Referendums C & D; PR Pharmaceuticals based in Fort Collins; and William W. Cimino, Ph.D., President of Sound Surgical in Louisville. Other topics covered include upcoming CBSA events, executive report, CBSA’s public policy process, regulatory update on compliance as a competitive advantage, and news briefs.
Denver, CO (PRWEB) July 21, 2005 -- The second issue of "The CBSA FOCUS," the Colorado BioScience Association's quarterly newsletter is now available. The announcement is made by Denise Brown, CBSA executive director, who says the Association's quarterly publication features an endorsement of Referendums C and D to the TABOR amendment, which will be on the Colorado ballot in November.
In keeping with its mission, the newsletter helps further share the many success stories and highlights of Colorado’s medical device and biotechnology industries.
In addition to the article on Referendums C and D, featured articles in the Summer FOCUS issue cover PR Pharmaceuticals based in Fort Collins and William W. Cimino, Ph.D., President of Sound Surgical in Louisville. Other topics covered include upcoming CBSA events, executive report, CBSA’s public policy process, regulatory update on compliance as a competitive advantage, and news briefs. Here’s a sampling of the feature articles and links to the full articles and PDF of the newsletter:
"Referendums C and D: Critical To Colorado’s Bioscience Industry" -- In November, Colorado voters will be asked to approve two ballot questions that address the state's fiscal crisis. These referendums could have a significant impact on the quality of Colorado's workforce and the state's infrastructure, key components of a sustainable climate for the bioscience industry. You can read the FOCUS article about Referendums C & D.
"The Executive Team At A Company Called PR Pharmaceuticals (PRP) Has A Knack For Making The Right Moves." That talent may soon reap huge benefits for millions of patients with diabetes and heart disease. PRP is the result of a 1998 merger between Micrel Limited, an Arizona drug delivery company founded by PRP's CEO Steve Howe, and the Fort Collins based Wildlife Pharmaceuticals. Today PRP is a privately owned company that develops and manufactures innovative sustained release drug delivery technologies for human and animal health.
"Taking Flight: From Aerospace Engineer To Medical Technology Entrepreneur, Sound Surgical's Founder Is Ready For Take-Off." It took leaving the aerospace industry to launch William W. Cimino, Ph.D. on a high-flying career path that engaged both his talent and his passion. "My first loves were always medicine and bio-engineering," he says. "So I made my move." Fifteen years later, Cimino is chairman and president of Sound Surgical Technologies of Louisville, Colorado.
Back to Drug News
|
|
|
|
|
|
|
|